Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NIPAL4 (Magnesium transporter NIPA4) is a transmembrane protein with nine helices, predominantly expressed in the granular layer of the epidermis. It primarily acts as a magnesium transporter, but also facilitates the transport of other divalent cations. NIPAL4 is central to epidermal lipid metabolism by participating in the synthesis of very long chain fatty acids and the formation/secretion of lamellar bodies, thus maintaining the integrity of the skin barrier. Pathogenic mutations in NIPAL4 are the second most common genetic cause of autosomal recessive congenital ichthyosis (ARCI), leading to abnormal lipid composition and barrier dysfunction characteristic of this disease. There is no clear evidence for approved drugs directly modulating NIPAL4, but molecular and cellular studies suggest that restoring skin lipid homeostasis, e.g., via retinoid mimetics, can partly compensate for its deficiency
Not established for drug targeting; ARCI symptoms can be partially ameliorated by retinoid-mimetic treatment, suggesting impact via restoration of epidermal lipid metabolism
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Magnesium transporter NIPA4 (NIPAL4).